Abstract
The subthalamic nucleus (STN) is a common anatomical target for deep brain stimulation (DBS) for the treatment of Parkinson's disease. However, the effects of stimulation may spread beyond the STN. Ongoing research aims to identify nearby anatomical structures where DBS-induced effects could be associated with therapeutic improvement or side effects. We previously found that DBS lead location determines the rate - abrupt vs. gradual - with which therapeutic effect washes out after stimulation is stopped. Those results suggested that electrical current spreads from the electrodes to two spatially distinct stimulation targets associated with different washout rates. In order to identify these targets we used computational models to predict the volumes of tissue activated during DBS in 14 Parkinson's patients from that study. We then coregistered each patient with a stereotaxic atlas and generated a probabilistic stimulation atlas to obtain a 3-dimensional representation of regions where stimulation was associated with abrupt vs. gradual washout. We found that the therapeutic effect which washed out gradually was associated with stimulation of the zona incerta and fields of Forel, whereas abruptly-disappearing therapeutic effect was associated with stimulation of STN itself. This supports the idea that multiple DBS targets exist and that current spread from one electrode may activate more than one of them in a given patient, producing a combination of effects which vary according to electrode location and stimulation settings.
Original language | English (US) |
---|---|
Article number | e99663 |
Journal | PloS one |
Volume | 9 |
Issue number | 8 |
DOIs | |
State | Published - Aug 6 2014 |
Externally published | Yes |
Bibliographical note
Funding Information:Portions of the analysis were performed using SCIRun, an open-source problem solving environment that was developed through grants from the National Center for Research Resources (5P40R012553-15) and the National Institute of General Medical Sciences (8 P41 GM103545-15) from the National Institutes of Health.